ABCB1 and neoplasm: In total, 27 of 85 primary tumours (32%) were scored as positive for ABCB1 by standard immunohistochemical analysis, 15/53 (28%) from the CNS9204 trial cohort and 12/32 (37.5%) from the CNS9904 cohort.